NRAS
Erasca Begins Phase III Trial of Naporafenib, Mekinist in NRAS-Mutant Melanoma
The study will explore the combination in melanoma patients who have progressed on treatment with immunotherapy.
Relay, Pfizer Testing CDK4, PI3Kα Inhibitors in Metastatic Breast Cancer Trial
Relay further disclosed a program in vascular malformations and an NRAS-selective inhibitor that it is planning to bring into clinical development in 2025.
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Immuneering Takes Lead Agent Into Phase II Trial Betting on Universal RAS Inhibition in Solid Tumors
Premium
The firm is evaluating IMM-1-104 in the Phase IIa portion of a trial involving patients with pancreatic cancer and RAS-mutant melanoma and NSCLC.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
May 9, 2022
InxMed Raises $15M in Extended Series B Funding
Mar 4, 2022